Federal Circuit holds that isolated DNA molecules are patent-eligible subject matter

Today the U.S. Court of Appeals for the Federal Circuit issued its much-anticipated opinion in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Fed. Cir. 2012).  In the decision, the Court held that claims directed to isolated DNA molecules and methods of screening potential anti-cancer therapeutics are patent-eligible subject matter.

My colleagues Gerard Norton and Jianming Jimmy Hao have published a more detailed summary of the Federal Circuit’s decision, available via this link.